Annual General Meeting - Meeting Materials

The Annual General Meeting (AGM) of Imagion Biosystems Limited (the Company) will be held virtually on Wednesday, 22 July 2020 at 11.00am (Melbourne……


Imagion Biosystems Market Herald Interview

We recently announced plans to conduct our first in-human study for MagSense in Australia later this year. In this Market Herald interview, watch IBX CEO Bob…


Appendix 3Y — Change in Director's Interest Notice

Imagion Biosystems has made the attached Appendix 3Y announcements in relation to change of Directors interest notice. Read Appendix 3Y — Change in Director's…


First in-human study update - webcast presentation

You can also register to watch the entire Zoom webcast on-demand by clicking here


Appendix 2A — Vesting of Performance Rights

Imagion Biosystems Limited advises that the 200,000 Performance Rights issued to Directors of the Company under the Company Long-term Incentive Plan on 14…


Investor Webcast Presentation

Imagion Biosystems has released an investor webcast presentation announcement to the market. View the webcast presentation.


Imagion announces plan to undertake first clinical study in Australia

Imagion announces plan to undertake first clinical study in Australia Live Webcast Scheduled Imagion Biosystems Limited (ASX: IBX), a company dedicated to…


Notice of Annual General Meeting and Explanatory Memorandum

TAKE NOTICE that the Annual General Meeting of Shareholders of the Company will be held at the time, date and place specified below: Time: 11.00 am…


Market Herald Interview

In May, Imagion signed a collaboration agreement with Siemens Healthineers to explore the utility of our MagSense nanoparticles as a contrast agent in MRI…


Imagion Nanoparticle Manufacturing Update

Imagion Biosystems Limited is pleased to report that the first phase of manufacturing of the MagSense™ HER2 nanoparticle formulation under Good…